CGMP/Finished Pharmaceuticals/Adulterated
Similar Posts
Howard I. Schwartz, M.D. Hollywood, FL. EIR issued 11/19/2020
Task Description Request Please post to the OII FOIA Electronic Reading Room
Record Date 11/19/2020
Short Title (70 char) Howard I. Schwartz, M.D. Hollywood, FL. EIR issued 11/19/2020
FEI Number 1000525885
Firm Name Howard I. Schwartz, M.D.
Record Type EIR
State FL
Establishment Type Clinical InvestVentilator Recall: Philips Respironics Removes Certain DreamStation Devices Due to Programming Errors That Can Result in Failed Therapy Modes
DreamStation devices may deliver incorrect therapy due to programming errors. Continued use could cause ineffective treatment or harm.Esophageal pH Monitoring Capsule Recall: Medtronic and Given Imaging Remove Bravo CF Capsule Delivery Devices
This communication is part of the Communications Pilot to Enhance the Medical Device Recall ProgramRegulatory Pharmaceutical Fellowship Program
Explore the FDA’s Regulatory Pharmaceutical Fellowship Program, a partnership with academia and industry, offering specialized training in regulatory science, policy, and drug development. Learn how to advance your career in the pharmaceutical field through this unique fellowship opportunity.Umovy may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Umovy, a product promoted and sold for joint pain on various websites, including www.umovy-usa.com, and possibly in some retail stores.FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations for these drugs.